Single photon detection for ultra-low dose Molecular Breast Imaging

乳房筛查是近30年前在英国引入的，主要依靠X光乳房X光检查。这项技术在癌症肿瘤和周围乳腺组织的密度有显著差异的情况下是有效的。大约三分之一的女性乳房组织密度较高，因此乳房X光检查无法清楚地显示肿瘤的图像，从而导致未诊断的癌症。乳房筛查的年龄逐渐从50-70岁延长到47-73岁。由于年轻女性乳房致密的比例较高，目前提供的乳房X光检查更不令人满意。克罗梅克已经发现，通过增加一种名为分子乳房成像(MBI)的核成像技术，作为乳房组织致密女性的主要筛查工具，早期诊断乳腺癌是可能的。MBI是一种技术，通过使用放射性示踪剂来识别肿瘤，然后由专业相机成像。与正常组织相比，示踪剂在恶性乳腺组织中的集中程度要大得多，因此恶性组织在图像上显示为一个明亮的区域。MBI目前的缺点是需要比乳房X光检查接收到的辐射剂量更高的辐射剂量和更长的测量时间。自2018年以来，Kromek一直与UCL和Nuth合作开发一种量子技术，以解决这些缺点并促进筛查路径的改变，以开发更快、更安全的MBI系统。Kromek开发了一种基于新一代单光子CZT探测器和概念上新型准直器的专有MBI相机设计。与新的3D图像重建方法相结合，新相机将能够揭示有关肿瘤及其结构的空间信息。这些信息将有助于显著增加癌症早期检测的机会，并改善准确诊断和成功治疗处方所需的癌症分期过程。该项目将通过证明用于MBI的单光子检测方法的可行性，促进低剂量量子技术的商业化。

Breast screening was introduced in the UK almost 30 years ago and relies principally on x-ray mammography. This technique is effective where there is a significant difference in the density of a cancer tumor and the surrounding breast tissue. Around a third of women have denser breast tissue, such that mammography is unable to clearly image tumors, resulting in undiagnosed cancers. The age for breast screening is gradually extending from 50-70 to 47-73\. As there is a higher prevalence of dense breasts in younger women, the current provision of mammography even less satisfactory.Kromek has identified that earlier diagnosis of breast cancers is possible with an addition of a nuclear imaging technology, Molecular Breast Imaging (MBI), as a primary screening tool for women with dense breast tissue. MBI is a technique whereby a radioactive tracer is used to identify a tumor that is then imaged by a specialist camera. The tracer is concentrated to a much greater extent in malignant breast tissue compared to normal tissue, therefore the malignant tissue shows up as a bright area on the image. MBI currently has the disadvantage of requiring a higher radiation dose than received with a mammogram and longer measurement time.Since 2018, Kromek has been engaged with UCL and NUTH in developing a quantum technology for a faster and safer MBI system addressing these shortcomings and facilitating a change in the screening pathways. Kromek has developed a proprietary MBI camera design based on a new generation of single photon CZT detectors and a conceptually new type of collimator. Combined with novel 3D image reconstruction methods, the new camera will allow uncovering spatial information about tumours and their structure. That information will help to significantly increase chances for early cancer detection and improve cancer staging process required for precise diagnostics and successful treatment prescription.The project will contribute towards the commercialisation of the low-dose quantum technology by proving the feasibility of he single-photon detection methodology for MBI.